Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - valganciclovir, quantity: 450 mg - tablet, film coated - excipient ingredients: povidone; stearic acid; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). valganciclovir is indicated for the prophylaxis of cmv infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; stearic acid; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir viatris is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids). valganciclovir viatris is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Canada - English - Health Canada

teva canada limited - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides

Canada - English - Health Canada

mint pharmaceuticals inc - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides

United States - English - NLM (National Library of Medicine)

par pharmaceutical - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - valganciclovir 450 mg - treatment of cytomegalovirus (cmv) retinitis : valganciclovir tablets, usp are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1) ]. prevention of cmv disease : valganciclovir tablets, usp are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1) ]. prevention of cmv disease : valganciclovir tablets, usp are indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2) ]. valganciclovir is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (eg, anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1)]. risk summary after oral administra

United States - English - NLM (National Library of Medicine)

avkare - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - valganciclovir 450 mg - treatment of cytomegalovirus (cmv) retinitis:  valganciclovir tablets, usp are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)] . prevention of cmv disease: valganciclovir tablets, usp are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1)] . prevention of cmv disease: valganciclovir tablets, usp are indicated for the prevention of cmv disease in heart transplant patients (4 months to 16 years of age) at high risk [see clinical studies (14.2)] . pediatric use information for pediatric kidney transplant patients ages 4 months to 16 years and for pediatric heart transplant patients ages 1 to less than 4 months is approved for ro

Canada - English - Health Canada

natco pharma (canada) inc - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride -

Canada - English - Health Canada

mylan pharmaceuticals ulc - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride -